<?xml version="1.0" encoding="utf-8" ?>
<INTERACTIONS>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>288-HMG-COA-REDUCTASE-INHIBITORS-(STATINS).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="XANTHINE OXYDASE INHIBITORS" code="M04AA0" /></DRUG1>
<DRUG2>
<CLASS name="ANTIPURINES" code="ANTIPUR" /></DRUG2>
<DESCRIPTION>Possibly serious medullary insufficiency</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>288-HMG-COA-REDUCTASE-INHIBITORS-(STATINS).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="XANTHINE OXYDASE INHIBITORS" code="M04AA0" /></DRUG1>
<DRUG2>
<CLASS name="THEOPHYLLINE (AND, BY EXTRAPOLATION, AMINOPHYLLINE)" code="R03DA" /></DRUG2>
<DESCRIPTION>With large doses of the inhibitor, increase of the plasma concentrations of theophylline due to inhibition of its metabolism. </DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and testing of the theohyllinemia up to two to three weeks after the beginning of the treatment with the inhibitor; if there is reason for it, adjustment of the dosage during the treatment with these substances together. </COMMENT>
</INTERACTION>
</INTERACTIONS>
